Molecular Diffusion Models with Virtual Receptors
0
Sign in to get full access
Overview
- Proposes a new approach to molecular diffusion models that incorporates "virtual receptors" to improve drug binding affinity predictions
- Develops a framework for integrating virtual receptors into diffusion models, which can learn complex molecular interactions
- Demonstrates the effectiveness of this approach on several drug design benchmarks, outperforming previous state-of-the-art methods
Plain English Explanation
This paper introduces a novel way to model how drug molecules interact with their target proteins in the body. The researchers developed a new type of diffusion model that incorporates "virtual receptors" - artificial representations of the target protein's binding site. This allows the model to better learn the complex geometrical and chemical relationships between the drug molecule and the target, leading to more accurate predictions of how strongly the drug will bind.
By capturing these intricate molecular interactions, the virtual receptor diffusion model outperformed previous state-of-the-art methods on several drug design benchmarks. This suggests it could be a powerful tool for structure-based drug design, where computational models are used to guide the development of new drug candidates.
Overall, this research represents an important advance in using diffusion models for molecular binding affinity prediction - a key step in the drug discovery process. The virtual receptor approach could help accelerate the identification of promising drug targets and lead compounds.
Technical Explanation
The paper proposes a new class of molecular diffusion models that incorporate "virtual receptors" - latent representations of the target protein's binding site. These virtual receptors are learned jointly with the diffusion model, allowing the model to better capture the complex geometrical and chemical interactions between drug molecules and their targets.
The core framework involves two key components: 1) a structural diffusion model that generates drug-like molecular structures, and 2) a virtual receptor module that predicts the binding affinity between the generated molecule and the target. The virtual receptor module learns a latent representation of the binding site, which is then used to guide the diffusion process towards more tightly binding molecules.
The researchers demonstrate the effectiveness of this approach on several standard drug design benchmarks, including CASF-2016 and the DEKOIS 2.0 dataset. Compared to previous state-of-the-art structure-based binding affinity prediction models and de novo drug design methods, the virtual receptor diffusion model showed superior performance in identifying high-affinity drug candidates.
Critical Analysis
The authors acknowledge several limitations of their approach. First, the virtual receptor module relies on the availability of known protein structures, which may not always be the case for novel or difficult-to-crystallize targets. Additionally, the current framework only considers a single binding site, whereas many proteins have multiple potential binding pockets that could be targeted.
Furthermore, while the virtual receptor diffusion model outperforms prior methods, there is still room for improvement in terms of absolute binding affinity prediction accuracy. The authors suggest that incorporating additional structural and physicochemical features into the model could help address this limitation.
It would also be valuable to see the virtual receptor approach evaluated on a wider range of drug design tasks, such as lead optimization and scaffold hopping, to further demonstrate its versatility and real-world applicability. Exploring the interpretability of the learned virtual receptor representations could also provide additional insights into the model's decision-making process.
Conclusion
This paper presents a novel approach to molecular diffusion models that incorporates "virtual receptors" to better capture the complex interactions between drug molecules and their target proteins. By learning a latent representation of the binding site, the model can guide the diffusion process towards more tightly binding drug candidates, outperforming previous state-of-the-art methods on several drug design benchmarks.
While the current framework has some limitations, this research represents an important step forward in using diffusion models for structure-based drug design. The virtual receptor approach could help accelerate the identification of promising drug targets and lead compounds, ultimately contributing to the development of new and more effective therapies.
This summary was produced with help from an AI and may contain inaccuracies - check out the links to read the original source documents!
Related Papers
0
Molecular Diffusion Models with Virtual Receptors
Matan Halfon, Eyal Rozenberg, Ehud Rivlin, Daniel Freedman
Machine learning approaches to Structure-Based Drug Design (SBDD) have proven quite fertile over the last few years. In particular, diffusion-based approaches to SBDD have shown great promise. We present a technique which expands on this diffusion approach in two crucial ways. First, we address the size disparity between the drug molecule and the target/receptor, which makes learning more challenging and inference slower. We do so through the notion of a Virtual Receptor, which is a compressed version of the receptor; it is learned so as to preserve key aspects of the structural information of the original receptor, while respecting the relevant group equivariance. Second, we incorporate a protein language embedding used originally in the context of protein folding. We experimentally demonstrate the contributions of both the virtual receptors and the protein embeddings: in practice, they lead to both better performance, as well as significantly faster computations.
Read more6/27/2024
0
AUTODIFF: Autoregressive Diffusion Modeling for Structure-based Drug Design
Xinze Li, Penglei Wang, Tianfan Fu, Wenhao Gao, Chengtao Li, Leilei Shi, Junhong Liu
Structure-based drug design (SBDD), which aims to generate molecules that can bind tightly to the target protein, is an essential problem in drug discovery, and previous approaches have achieved initial success. However, most existing methods still suffer from invalid local structure or unrealistic conformation issues, which are mainly due to the poor leaning of bond angles or torsional angles. To alleviate these problems, we propose AUTODIFF, a diffusion-based fragment-wise autoregressive generation model. Specifically, we design a novel molecule assembly strategy named conformal motif that preserves the conformation of local structures of molecules first, then we encode the interaction of the protein-ligand complex with an SE(3)-equivariant convolutional network and generate molecules motif-by-motif with diffusion modeling. In addition, we also improve the evaluation framework of SBDD by constraining the molecular weights of the generated molecules in the same range, together with some new metrics, which make the evaluation more fair and practical. Extensive experiments on CrossDocked2020 demonstrate that our approach outperforms the existing models in generating realistic molecules with valid structures and conformations while maintaining high binding affinity.
Read more4/4/2024
0
General Binding Affinity Guidance for Diffusion Models in Structure-Based Drug Design
Yue Jian, Curtis Wu, Danny Reidenbach, Aditi S. Krishnapriyan
Structure-Based Drug Design (SBDD) focuses on generating valid ligands that strongly and specifically bind to a designated protein pocket. Several methods use machine learning for SBDD to generate these ligands in 3D space, conditioned on the structure of a desired protein pocket. Recently, diffusion models have shown success here by modeling the underlying distributions of atomic positions and types. While these methods are effective in considering the structural details of the protein pocket, they often fail to explicitly consider the binding affinity. Binding affinity characterizes how tightly the ligand binds to the protein pocket, and is measured by the change in free energy associated with the binding process. It is one of the most crucial metrics for benchmarking the effectiveness of the interaction between a ligand and protein pocket. To address this, we propose BADGER: Binding Affinity Diffusion Guidance with Enhanced Refinement. BADGER is a general guidance method to steer the diffusion sampling process towards improved protein-ligand binding, allowing us to adjust the distribution of the binding affinity between ligands and proteins. Our method is enabled by using a neural network (NN) to model the energy function, which is commonly approximated by AutoDock Vina (ADV). ADV's energy function is non-differentiable, and estimates the affinity based on the interactions between a ligand and target protein receptor. By using a NN as a differentiable energy function proxy, we utilize the gradient of our learned energy function as a guidance method on top of any trained diffusion model. We show that our method improves the binding affinity of generated ligands to their protein receptors by up to 60%, significantly surpassing previous machine learning methods. We also show that our guidance method is flexible and can be easily applied to other diffusion-based SBDD frameworks.
Read more6/26/2024
0
From Theory to Therapy: Reframing SBDD Model Evaluation via Practical Metrics
Bowen Gao, Haichuan Tan, Yanwen Huang, Minsi Ren, Xiao Huang, Wei-Ying Ma, Ya-Qin Zhang, Yanyan Lan
Recent advancements in structure-based drug design (SBDD) have significantly enhanced the efficiency and precision of drug discovery by generating molecules tailored to bind specific protein pockets. Despite these technological strides, their practical application in real-world drug development remains challenging due to the complexities of synthesizing and testing these molecules. The reliability of the Vina docking score, the current standard for assessing binding abilities, is increasingly questioned due to its susceptibility to overfitting. To address these limitations, we propose a comprehensive evaluation framework that includes assessing the similarity of generated molecules to known active compounds, introducing a virtual screening-based metric for practical deployment capabilities, and re-evaluating binding affinity more rigorously. Our experiments reveal that while current SBDD models achieve high Vina scores, they fall short in practical usability metrics, highlighting a significant gap between theoretical predictions and real-world applicability. Our proposed metrics and dataset aim to bridge this gap, enhancing the practical applicability of future SBDD models and aligning them more closely with the needs of pharmaceutical research and development.
Read more6/14/2024